



# Fungal Organisms

Disclaimer: This document is for educational purposes and not to guide patient-level therapeutic decisions




## Fungal Cell Wall with Antifungal Targets



### KEY

- Routinely active
- Variable activity
- No or limited activity



\*Amphotericin B has no appreciable activity against *Aspergillus terreus*

\*\*Fluconazole is considered standard of care for treatment of *Coccidioides* infections but has variable activity against other dimorphic fungi

\*\*\*Flucytosine is primarily used in combination with other antifungals for treatment given rapid development of resistance when administered as monotherapy

\*\*\*\*Ibrexafungerp is FDA approved for treatment of vulvovaginal candidiasis (June 2021). Research into use for systemic fungal infections is currently in process